TEVA

Teva Pharmaceutical IndustriesC

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$44.00

+37.4% vs current

Most likely

Base case

45%

Probability

Target price

$39.80

+24.3% vs current

B-

Bear case

25%

Probability

Target price

$28.00

-12.6% vs current

AI sentiment snapshot

Latest data as of 2026-06-11

AI commentary

Primary-source evidence remains constructive but still monitoring-oriented. Teva's April 29 materials showed solid Q1 execution, maintained revenue guidance, and several concrete neuroscience and biosimilar milestones, but they also confirmed ongoing generic pressure and a margin-management burden around Emalex. Shares were about $33.58 as of June 10, 2026, below both the June 9 anchor of $34.45 and the packet's median analyst target, suggesting the market is not fully underwriting the strategic upside yet. Fresh analyst revision data are not available in the packet, so confidence should stay below high-conviction levels.

RankAlpha Sentiment Codex - 2026-06-11

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalystOlanzapine LAI regulatory progress could sharpen the late-2026 launch setupMedium impact

Teva said its olanzapine LAI NDA was accepted by the FDA in February 2026, EU MAA acceptance was expected in Q2 2026, and it is preparing for a Q4 2026 launch subject to approval; confirmation of those regulatory steps would support the neuroscience growth mix. [#SEC-8K-2026-04-29]

2026-09-30eventEmalex closing is the clearest dated portfolio eventMedium impact

Teva's April 29 acquisition announcement says Emalex is expected to close by Q3 2026, with $700 million upfront, up to $200 million in milestones, and management intending to mitigate near-term margin dilution while adding NDA-ready ecopipam to the neuroscience pipeline. [#SEC-8K-2026-04-29]

2026-12-31catalystDuvakitug and broader late-stage updates remain the main organic upside pathMedium impact

Teva said duvakitug Phase 3 enrollment is on target after durable Phase 2b maintenance data, and management expects meaningful 2026 updates across five additional innovative programs; delivery against that slate is the best route to a higher-quality growth multiple. [#SEC-8K-2026-04-29]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-11 • Updated nightlySource: Internal modelMethodology